Clinical Trials Logo
  1. Home
  2. Leukemia, Chronic Myeloid
  3. NCT02389920

Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib

Leukemia, Chronic Myeloid Clinical Trial

Clinical Trial Summary

Describe the purpose of the study: This study aims to evaluate the improvement of Dasatinib-related adverse events and to evaluate the treatment effect and safety by measuring the genetic response of nilotinib with nilotinib 400mg BID for 12 months in Philadelphia chromosome-positive chronic myeloid leukemia patients intolerant to Dasatinib.

Clinical Trial Description

n/a

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02389920
Study type Interventional
Source Samsung Medical Center
Contact
Status Not yet recruiting
Phase Phase 4
Start date April 2015
Completion date December 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT04384848 - The EMPATHY Pilot Study N/A
Recruiting NCT03515018 - Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients Phase 3
Active, not recruiting NCT02381379 - Malaysia Stop Tyrosine Kinase Inhibitor Trial Phase 3
Active, not recruiting NCT02852486 - Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response Phase 2
Recruiting NCT02326311 - Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response Phase 3
Terminated NCT02627573 - Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT Phase 2
Withdrawn NCT02973711 - A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML Phase 1/Phase 2
Terminated NCT01761695 - Chronic Myelod Leukemia Registry at Asan Medical Center